ARGX 116

Drug Profile

ARGX 116

Alternative Names: ARGX-116

Latest Information Update: 09 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator argenx
  • Developer argenx; Staten Biotechnology
  • Class Antibodies; Antihyperlipidaemics
  • Mechanism of Action Apolipoprotein C-III inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Dyslipidaemias

Most Recent Events

  • 06 Mar 2017 Staten Biotech exercises its exclusive option to license ARGX 116 for Dyslipidaemias
  • 06 Mar 2017 Early research in Dyslipidaemias in Netherlands, USA (Parenteral) before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top